DBVT
DBV Technologies S.A.
Next earnings Jul 27, 2026 · consensus $-0.10 EPS, $1.40M rev
Last earnings +3.4% on 2026-04-30
$15.82
▼ -1.13%$15.82▲ +78.15%
over 1Y
L $8.51H $24.54
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-1.1%
1W-1.2%
1M-13.2%
3M-24.9%
YTD-17.0%
1Y+78.2%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Pre-revenue biotech with one shot on goal (Viaskin Peanut) priced at $4.75B on $5.6M sales — speculative, not investable on fundamentals.
Revenue $5.64M · FY2025
DBVT is a late-stage specialty biopharma whose entire equity story hinges on one asset: the Viaskin Peanut epicutaneous patch for pediatric peanut allergy. The 10-K MD&A is explicit that 2026's focus is 'commercialization and laying the groundwork to transform the lives of children living with peanut allergy' — meaning the company is still pre-approval, and the FY2025 revenue line of $5.64M is not a commercial business, it's residual/collaboration income. Putting a $4.75B market cap on that produces a P/S of 843.6x, which is not a valuation in any conventional sense — it is a probability-weighted bet on FDA approval and launch.
The fundamentals reinforce that this is a cash-burn story, not an earnings story. FY2025 net loss widened to -$147M (YoY -29.0%) on $117M of R&D, operating cash flow was -$121M, and accumulated deficit reached -$393M. The one piece of good news in the filing is the financing: the March 2025 PIPE plus the January 2026 warrant exercises (triggered by positive VITESSE topline on Dec 16, 2025) lifted cash to $194M at year-end and added a further $195M of gross proceeds post-period. Management states this is 'sufficient to pursue operations and prepare for the potential U.S. launch of the VIASKIN Peanut patch for children aged 4-7, if approved' — note the 'if approved' caveat.
Is DBVT a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~60d expiry
- Long put 16 @ ~1.26 est
- Short put 14 @ ~0.43 est
debit $83max +$117max −$83BE 15.17
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $5.71M | $4.84M | $15.7M | $4.15M | $5.64M |
| Gross profit | — | — | — | — | — |
| Operating income | -$98.6M | -$96.6M | -$76.4M | -$117M | -$147M |
| Net income | -$97.8M | -$96.3M | -$72.7M | -$114M | -$147M |
| Diluted EPS | -$1.78 | -$1.24 | -$0.76 | -$1.17 | -$1.05 |
| Net margin | -1713.5% | -1987.5% | -462.4% | -2744.4% | -2607.3% |
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$743M
EV / EBITDA—
EV / Sales131.9
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-15.7%
FCF yield-13.0%
Quality & risk
ROIC (est.)-68.3%
Free cash flow-$122M
Total debt$1.32M
Net cash$193M
Altman Z-Score5.04 safe
Piotroski F-Score4/8
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+116.2%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRecent disclosure tone has been improving.
- 8-K Other event2026-06-29
- 8-K Officer / director change2026-06-05
Officer/director change disclosed; no financial impact stated.
- 8-K Charter / bylaws change2026-06-03
Annual meeting vote results and bylaw amendments approved.
- DEF 14A Proxy statement2026-05-11
Proxy for annual meeting; routine governance items.
- 8-K Officer / director change2026-05-05
Officer/director appointment or departure disclosed.
- 8-K Earnings results2026-04-30
FY2025 10-K amendment; corrects/adds disclosures, no restatement signaled.
- 10-Q Quarterly report2026-04-30
FY2025 10-K amendment; corrects/adds disclosures, no restatement signaled.
- 10-K/A Restated periodic report2026-04-30
FY2025 10-K amendment; corrects/adds disclosures, no restatement signaled.
- 8-K Earnings results2026-03-26
FY2025: $194M cash post-PIPE, positive VITESSE Phase 3 data, BLA pathway clarified.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-292026-06-29open ↗8-KPeriod ending 2026-06-032026-06-05open ↗S-8Filing2026-06-04open ↗8-KPeriod ending 2026-06-032026-06-03open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-13open ↗SCHEDULE 13G/AFiling2026-05-13open ↗SCHEDULE 13G/AFiling2026-05-12open ↗ARSPeriod ending 2025-12-312026-05-11open ↗DEF 14APeriod ending 2026-06-032026-05-11open ↗8-KPeriod ending 2026-04-302026-05-05open ↗SCHEDULE 13G/AFiling2026-05-05open ↗
Frequently asked
- Is DBV Technologies S.A. (DBVT) a buy?
- DBVT currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Pre-revenue biotech with one shot on goal (Viaskin Peanut) priced at $4.75B on $5.6M sales — speculative, not investable on fundamentals.
- What is DBV Technologies S.A.'s quality score?
- DBVT scores 41.202792940320236/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001613780, latest 10-Q filed 2026-04-30) · EODHD · Proprietary analysis · as of 6/25/2026, 2:33:33 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
AI-generated analysis, produced by our proprietary engine from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 25, 2026, 10:33 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.